scout
Opinion|Videos|October 28, 2024

Integrating Tisotumab Vedotin into Ovarian Cancer Therapy

Panelists discuss the integration of tisotumab vedotin into ovarian cancer therapy, covering its role in treatment approaches, patient selection, adverse event management, clinical pearls, challenges in practice, and the implications of the drug’s payload on treatment efficacy.

Video content above is prompted by the following:

  • Where does tisotumab vedotin fit in your current treatment approach?
  • In which patients do you consider this treatment option?
  • Adverse event management and clinical pearls
  • What challenges do you see in practice with tisotumab vedotin, and how do you approach associated management?
  • Payload of tisotumab vedotin

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME